Display options
Share it on

J Ophthalmol. 2016;2016:4917659. doi: 10.1155/2016/4917659. Epub 2016 Jan 20.

Pupil Dilation with Intracameral Epinephrine Hydrochloride during Phacoemulsification and Intraocular Lens Implantation.

Journal of ophthalmology

A-Yong Yu, Hua Guo, Qin-Mei Wang, Fang-Jun Bao, Jing-Hai Huang

Affiliations

  1. The Eye Hospital of Wenzhou Medical University, Wenzhou 325000, China.

PMID: 26904274 PMCID: PMC4745390 DOI: 10.1155/2016/4917659

Abstract

Objective. To investigate mydriatic effect of intracamerally injected epinephrine hydrochloride during phacoemulsification and intraocular lens (IOL) implantation. Methods. Eighteen cataract patients for bilateral phacoemulsification were enrolled. To dilate pupil, one eye was randomly selected to receive intracamerally 1 mL epinephrine hydrochloride 0.001% for 1 minute after corneal incision (intracameral group), and the contralateral eye received 3 drops of compound tropicamide 0.5% and phenylephrine 0.5% at 5-minute intervals 30 minutes before surgery (topical group). Pupil diameters were measured before corneal incision, before ophthalmic viscoelastic device (OVD) injection, after OVD injection, before IOL implantation, and at the end of surgery. Results. At each time point, the mean pupil diameter in the intracameral group was 2.20 ± 0.08, 5.09 ± 0.20, 6.76 ± 0.19, 6.48 ± 0.18, and 5.97 ± 0.24 mm, respectively, and in the topical group it was 7.98 ± 0.15, 7.98 ± 0.15, 8.53 ± 0.14, 8.27 ± 0.16, and 7.93 ± 0.20 mm, respectively. The topical group consistently had larger mydriatic effects than the intracameral group (P < 0.05). The onset of mydriatic effect was rapid in the intracameral group. There was no difference in surgical performance or other parameters between groups. Conclusions. Intracameral epinephrine hydrochloride appears to be an alternative to the mydriatic modalities for phacoemulsification and IOL implantation. In comparison with topical mydriatics, intracameral epinephrine hydrochloride offers easier preoperative preparation, more rapid pupil dilation, and comparable surgical performance.

References

  1. Acta Ophthalmol Scand. 2004 Apr;82(2):144-7 - PubMed
  2. Dev Ophthalmol. 2010;47:148-59 - PubMed
  3. Cutan Ocul Toxicol. 2010 Mar;29(1):41-9 - PubMed
  4. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2927-31 - PubMed
  5. Ophthalmic Surg. 1989 Feb;20(2):132-40 - PubMed
  6. Curr Opin Ophthalmol. 2009 Jan;20(1):37-41 - PubMed
  7. Invest Ophthalmol. 1971 Jul;10(7):523-33 - PubMed
  8. Br J Ophthalmol. 1994 Feb;78(2):95-8 - PubMed
  9. Optom Vis Sci. 2011 Aug;88(8):940-9 - PubMed
  10. Ophthalmic Surg. 1983 Jan;14(1):41-5 - PubMed
  11. Curr Pharm Des. 2009;15(23):2724-50 - PubMed
  12. Drugs Aging. 1997 Nov;11(5):352-60 - PubMed
  13. J Cataract Refract Surg. 2008 Feb;34(2):280-3 - PubMed
  14. J Ocul Pharmacol Ther. 2001 Jun;17(3):249-53 - PubMed
  15. J Cataract Refract Surg. 2007 Jan;33(1):101-3 - PubMed
  16. J Cataract Refract Surg. 2011 Feb;37(2):341-8 - PubMed
  17. J Ocul Pharmacol Ther. 1998 Aug;14(4):357-61 - PubMed
  18. J Cataract Refract Surg. 2009 Feb;35(2):273-6 - PubMed
  19. J Cataract Refract Surg. 2008 Nov;34(11):1990-1 - PubMed
  20. Am J Optom Physiol Opt. 1982 Feb;59(2):162-77 - PubMed
  21. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5336-8 - PubMed
  22. J Cataract Refract Surg. 2003 Dec;29(12):2366-71 - PubMed
  23. J Cataract Refract Surg. 2003 Dec;29(12):2281-3 - PubMed

Publication Types